Select your Market
{{ userContent.title }}
Financial results of fiscal 2023
Forecast for fiscal 2024
| Fiscal 2023 (in € billion) | Change (in %, compared to 2022) | Organic change (in %, compared to 2022) |
|---|---|---|---|
Group net sales | 21.0 | -5.6 | -1.6 |
EBITDA pre | 5.9 | ‑14.2 | ‑9.0 |
Life Science sales | 9.3 | -10.6 | -7.9 |
Healthcare sales | 8.1 | 2.7 | 8.5 |
Electronics sales | 3.7 | ‑8.8 | ‑5.1 |
We delivered solid results in a transitional year 2023 despite difficult market conditions. Now, we are fully focusing on gradually returning to growth during fiscal 2024.
Our CEO Belén Garijo comments on the fiscal 2023 results.
Detailed information about the development of our business in fiscal 2023.
Downloads for the Media
Additional Downloads
Press Releases
The Group demonstrated the robustness of its diversified business model in a challenging market environment.
2024/03/07
Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more
